Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Momenta
Momenta
J&J clears PhII for rare blood disorder with drug from $6.5B Momenta buyout
J&J clears PhII for rare blood disorder with drug from $6.5B Momenta buyout
Endpoints
JNJ
Momenta
Janssen
nipocalimab
clinical trials
Flag link:
Astrazeneca shows megamergers were still possible in 2020
Astrazeneca shows megamergers were still possible in 2020
EP Vantage
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Bayer
Asklepios
Merck
VelosBio
Gilead Sciences
Forty Seven
Immunomedics
JNJ
Momenta
Flag link:
The top 5 pharma M&A deals of 2020
The top 5 pharma M&A deals of 2020
Pharmaforum
M&A
AstraZeneca
Alexion
Gilead Sciences
Immunomedics
Forty Seven
JNJ
Momenta
Sanofi
Principia Biopharma
Flag link:
Amphastar squeezes partners Momenta, Sandoz for $60M in Lovenox settlement
Amphastar squeezes partners Momenta, Sandoz for $60M in Lovenox settlement
Fierce Pharma
Sanofi
bloodthinners
Lovenox
generics
Amphastar
Momenta
Sandoz
Flag link:
Momenta Moves On
Momenta Moves On
Motley Fool
Momenta
earnings
biosimilars
M281
M254
Flag link:
The Winners And Losers Of JP Morgan Monday
The Winners And Losers Of JP Morgan Monday
Forbes
JPMHC 2018
Cellular Biomedicine
Alder Biopharmaceuticals
Nevro
Insulet
PTC Therapeutics
Axovant Sciences
Momenta
Natus Medical
Oxford Immunotec
EXACT Sciences
Flag link:
Momenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows
Momenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows
Yahoo/Zacks.com
Momenta
earnings
biosimilars
M834
Orencia
Flag link:
Teva catches break as warning letter looks to delay Momenta Copaxone generic
Teva catches break as warning letter looks to delay Momenta Copaxone generic
Fierce Pharma
Teva Pharmaceutical
Momenta
Copaxone
MS
multiple sclerosis
generics
Flag link:
Shire punts late-stage biosimilars of Humira and Enbrel back to Momenta, Coherus
Shire punts late-stage biosimilars of Humira and Enbrel back to Momenta, Coherus
Endpoints
Shire
biosimilars
Humira
Enbrel
Momenta
Flag link:
Here are 13 MA cancer biotechs hoping to make waves next month
Here are 13 MA cancer biotechs hoping to make waves next month
Bizjournals.com
Boston
biotech
ASCO 2016
Ariad Pharmaceuticals
Immunogen
Ziopharm
Vertex Pharmaceuticals
Tokai
Infinity Pharmaceuticals
Momenta
Merrimack
Tesaro
Syndax
Kyropharm
Foundation Medicine
Cerulean Pharma
Flag link:
Mylan, Momenta Team Up To Develop Biosimilar Drugs
Mylan, Momenta Team Up To Develop Biosimilar Drugs
Investors.com
Mylan Labs
Momenta
biosimilars
R&D
Flag link:
Novartis off to scorching start with Copaxone generic Glatopa
Novartis off to scorching start with Copaxone generic Glatopa
Fierce Pharma Marketing
Novartis
Copaxone
generics
Glatopa
MS
multiple scleroiss
Momenta
Sandoz
Flag link:
It's Teva vs. Momenta/Sandoz for Copaxone patients, with Mylan's version MIA
It's Teva vs. Momenta/Sandoz for Copaxone patients, with Mylan's version MIA
Fierce Pharma Marketing
Teva Pharmaceutical
Momenta
Sandoz
generics
Novartis
Copaxone
MS
multiple sclerosis
Flag link:
U.S. court nixes Teva's Copaxone patent--again
U.S. court nixes Teva's Copaxone patent--again
Fierce Pharma
Copaxone
patents
Teva Pharmaceuticals
generics
Momenta
Novartis
Sandoz
Flag link:
16 Biotech Stocks Moving Off The ASCO Conference
16 Biotech Stocks Moving Off The ASCO Conference
Yahoo/Benzinga
biotech
ASCO
Bristol-Myers Squibb
Immunogen
Oncothyreon
Clovis Oncology
CTI BioPharma
Exelixis
Roche
Amgen
AstraZeneca
Puma Biotechnology
Vascular Biogenics
Immunomedics
Momenta
Eli Lilly
Juno Therapeutics
Express Scripts
Flag link:
Momenta reports 1Q loss
Momenta reports 1Q loss
Yahoo/AP
Momenta
earnings
Flag link:
Drugmakers Oppose Teva Bid to Delay Copaxone Rivals
Drugmakers Oppose Teva Bid to Delay Copaxone Rivals
Bloomberg
Teva
Copaxone
MS
multiple sclerosis
Momenta
generics
Sandoz
Mylan
Flag link:
Momenta Pharmaceuticals Slumps: MNTA Falls 16.9% in Session
Momenta Pharmaceuticals Slumps: MNTA Falls 16.9% in Session
Yahoo/Zacks.com
Momenta
Flag link:
Supreme Court to decide patent dispute over multiple sclerosis treatment
Supreme Court to decide patent dispute over multiple sclerosis treatment
Yahoo/AP
Supreme Court
MS
multiple sclerosis
Copaxone
Teva Pharmaceuticals
Sandoz
Mylan
Momenta
Flag link:
Wider-Than-Expected Loss at Momenta
Wider-Than-Expected Loss at Momenta
Zacks
Momenta
earnings
Flag link:
Pages
1
2
3
4
5
next ›
last »